Skip to main content
. Author manuscript; available in PMC: 2009 Jan 30.
Published in final edited form as: Chem Biol Interact. 2006 Dec 16;171(2):165–176. doi: 10.1016/j.cbi.2006.12.006

Figure 6.

Figure 6

Traditional and computational approaches to selection of the Maximum Recommended Starting Dose (MRSD) for Phase 1 clinical trials.

Figure was reprinted from Regulatory Toxicology and Pharmacology 40: 185–206 (2004), “Estimating the safe and staring dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose”, by J.F. Contrera, E.J. Matthews, N.L. Kruhlak, and R. D. Benz [79], with permission from Elsevier.